AstraZeneca Defends Pulmicort Patents At Fed. Circ.

Law360, New York (August 12, 2013, 4:31 PM EDT) -- AstraZeneca PLC on Monday asked the Federal Circuit to block four generic-drug makers from launching no-name versions of its Pulmicort Respules pediatric asthma medication, saying a lower court relied too heavily on expert testimony in finding one of its patents as obvious and anticipated.

AstraZeneca’s attorney Christopher N. Sipes told a three-judge panel at oral arguments on Monday that New Jersey U.S. District Judge Renee Marie Bumb improperly combined a prior art article of a defendant expert with that same expert's witness testimony to invalidate a...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.